Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: PF-04136309
DRUG: Nab-paclitaxel
DRUG: Gemcitabine

Sponsor

Pfizer